We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hologic (HOLX) Falls More Steeply Than Broader Market: What Investors Need to Know
Read MoreHide Full Article
In the latest market close, Hologic (HOLX - Free Report) reached $77.38, with a -0.77% movement compared to the previous day. The stock's change was less than the S&P 500's daily loss of 0.04%. Meanwhile, the Dow experienced a drop of 0.03%, and the technology-dominated Nasdaq saw an increase of 0.03%.
Heading into today, shares of the medical device maker had gained 1.21% over the past month, outpacing the Medical sector's loss of 0.6% and lagging the S&P 500's gain of 2.57% in that time.
The upcoming earnings release of Hologic will be of great interest to investors. The company's earnings report is expected on May 2, 2024. In that report, analysts expect Hologic to post earnings of $0.98 per share. This would mark a year-over-year decline of 7.55%. In the meantime, our current consensus estimate forecasts the revenue to be $1 billion, indicating a 2.49% decline compared to the corresponding quarter of the prior year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $4.02 per share and revenue of $4.02 billion, indicating changes of +1.52% and -0.19%, respectively, compared to the previous year.
Any recent changes to analyst estimates for Hologic should also be noted by investors. These latest adjustments often mirror the shifting dynamics of short-term business patterns. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Hologic currently has a Zacks Rank of #3 (Hold).
From a valuation perspective, Hologic is currently exchanging hands at a Forward P/E ratio of 19.42. This signifies a discount in comparison to the average Forward P/E of 25.38 for its industry.
Meanwhile, HOLX's PEG ratio is currently 2.64. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As the market closed yesterday, the Medical - Instruments industry was having an average PEG ratio of 2.39.
The Medical - Instruments industry is part of the Medical sector. With its current Zacks Industry Rank of 81, this industry ranks in the top 33% of all industries, numbering over 250.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Hologic (HOLX) Falls More Steeply Than Broader Market: What Investors Need to Know
In the latest market close, Hologic (HOLX - Free Report) reached $77.38, with a -0.77% movement compared to the previous day. The stock's change was less than the S&P 500's daily loss of 0.04%. Meanwhile, the Dow experienced a drop of 0.03%, and the technology-dominated Nasdaq saw an increase of 0.03%.
Heading into today, shares of the medical device maker had gained 1.21% over the past month, outpacing the Medical sector's loss of 0.6% and lagging the S&P 500's gain of 2.57% in that time.
The upcoming earnings release of Hologic will be of great interest to investors. The company's earnings report is expected on May 2, 2024. In that report, analysts expect Hologic to post earnings of $0.98 per share. This would mark a year-over-year decline of 7.55%. In the meantime, our current consensus estimate forecasts the revenue to be $1 billion, indicating a 2.49% decline compared to the corresponding quarter of the prior year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $4.02 per share and revenue of $4.02 billion, indicating changes of +1.52% and -0.19%, respectively, compared to the previous year.
Any recent changes to analyst estimates for Hologic should also be noted by investors. These latest adjustments often mirror the shifting dynamics of short-term business patterns. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Hologic currently has a Zacks Rank of #3 (Hold).
From a valuation perspective, Hologic is currently exchanging hands at a Forward P/E ratio of 19.42. This signifies a discount in comparison to the average Forward P/E of 25.38 for its industry.
Meanwhile, HOLX's PEG ratio is currently 2.64. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As the market closed yesterday, the Medical - Instruments industry was having an average PEG ratio of 2.39.
The Medical - Instruments industry is part of the Medical sector. With its current Zacks Industry Rank of 81, this industry ranks in the top 33% of all industries, numbering over 250.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.